Maurits W. C. B. Sanders

Maurits W. C. B. Sanders

Auto-generated profile, based on publicly available information

Maurits W. C. B. Sanders

Department of Child Neurology, Brain Center University Medical Center Utrecht the Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2019 in Epilepsia
Verified
Journal Article
Closed access
PDF file
CBCarmen Barba
Carmen Barba
JCJudith Helen Cross
Judith Helen Cross
KBKees Braun
Kees Braun
MCMassimo Cossu
Massimo Cossu
KKKerstin Alexandra Klotz
Kerstin Alexandra Klotz
RGRenzo Guerrini
Renzo Guerrini

17 October 2019 in Epilepsia Open
Verified
Journal Article
Open access
PDF file
MSMaurits W. C. B. Sanders
Maurits W. C. B. Sanders
CLCynthia M. C. Lemmens
Cynthia M. C. Lemmens
FJFloor E. Jansen
Floor E. Jansen
EBEva H. Brilstra
Eva H. Brilstra
BKBobby P. C. Koeleman
Bobby P. C. Koeleman
T(the Dutch Collaborative Epilepsy Surgery Program (LWEC)
the Dutch Collaborative Epilepsy Surgery Program (LWEC)
Objective: Genetic causes are increasingly identified in patients with focal epilepsy. These genetic causes may be related to the effectiveness of epilepsy surgery. We aimed to assess the use and yield of genetic testing in a large cohort of patients who were evaluated for epilepsy surgery.Methods: We performed a retrospective single‐center consecutive cohort study of patients who were evaluated for surgery between 1990 and 2016. Within this cohort, we assessed the use of genetic testing—either before or after presurgical decision‐making. We evaluated genetic results as well as the outcome of presurgical decision‐making and surgery, and compared these end points for different subgroups—especially MRI‐positive vs MRI‐negative patients. Patients with tuberous sclerosis (TSC) and KRIT1 mutations were excluded from analysis.Results: Of the 2385 epilepsy patients who were evaluated for surgery, 1280 (54%) received surgical treatment in our center. Of the entire cohort, 325 (14%) underwent genetic testing, comprising 156 of 450 MRI‐negative patients (35%) vs 169 of 1935 MRI‐positive patients (9%). A genetic cause of epilepsy was found in 40 of the 325 patients (12%, 2% of the entire cohort), mainly consisting of mutations in ion channel function and synaptic transmission genes, and mTOR pathway gene mutations. Three of the seven patients with mTOR pathway gene mutations underwent surgery; two achieved complete seizure freedom. One of the 17 patients with germline mutations in ion channel function and synaptic transmission genes received resective surgery but was not rendered seizure‐free; two other patients underwent invasive intracranial EEG‐monitoring before being rejected.Significance: This study shows that genetic testing is increasingly applied in focal epilepsy patients who are considered for epilepsy surgery. The diagnostic yield of genetic testing is highest in next generation sequencing techniques, and the outcome of genetic testing assists selecting eligible patients for invasive intracranial monitoring and resective surgery.

27 February 2024 in Neurology
Verified
Journal Article
Open access
MSMaurits W. Sanders
Maurits W. Sanders
IWIskander Van der Wolf
Iskander Van der Wolf
FJFloor E. Jansen
Floor E. Jansen
EAEleonora Aronica
Eleonora Aronica
CHChristoph Helmstaedter
Christoph Helmstaedter
A(as the European Epilepsy Brain Bank Consortium (EEBB)
as the European Epilepsy Brain Bank Consortium (EEBB)
Patients with presumed nonlesional focal epilepsy-based on either MRI or histopathologic findings-have a lower success rate of epilepsy surgery compared with lesional patients. In this study, we aimed to characterize a large group of patients with focal epilepsy who underwent epilepsy surgery despite a normal MRI and had no lesion on histopathology. Determinants of their postoperative seizure outcomes were further studied. We designed an observational multicenter cohort study of MRI-negative and histopathology-negative patients who were derived from the European Epilepsy Brain Bank and underwent epilepsy surgery between 2000 and 2012 in 34 epilepsy surgery centers within Europe. We collected data on clinical characteristics, presurgical assessment, including genetic testing, surgery characteristics, postoperative outcome, and treatment regimen. Of the 217 included patients, 40% were seizure-free (Engel I) 2 years after surgery and one-third of patients remained seizure-free after 5 years. Temporal lobe surgery (adjusted odds ratio [AOR]: 2.62; 95% CI 1.19-5.76), shorter epilepsy duration (AOR for duration: 0.94; 95% CI 0.89-0.99), and completely normal histopathologic findings-versus nonspecific reactive gliosis-(AOR: 4.69; 95% CI 1.79-11.27) were significantly associated with favorable seizure outcome at 2 years after surgery. Of patients who underwent invasive monitoring, only 35% reached seizure freedom at 2 years. Patients with parietal lobe resections had lowest seizure freedom rates (12.5%). Among temporal lobe surgery patients, there was a trend toward favorable outcome if hippocampectomy was part of the resection strategy (OR: 2.94; 95% CI 0.98-8.80). Genetic testing was only sporadically performed. This study shows that seizure freedom can be reached in 40% of nonlesional patients with both normal MRI and histopathology findings. In particular, nonlesional temporal lobe epilepsy should be regarded as a relatively favorable group, with almost half of patients achieving seizure freedom at 2 years after surgery-even more if the hippocampus is resected-compared with only 1 in 5 nonlesional patients who underwent extratemporal surgery. Patients with an electroclinically identified focus, who are nonlesional, will be a promising group for advanced molecular-genetic analysis of brain tissue specimens to identify new brain somatic epilepsy genes or epilepsy-associated molecular pathways.

1 January 2021 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
BBBarbora Benova
Barbora Benova
MSMaurits W.C.B. Sanders
Maurits W.C.B. Sanders
AUAnna Mészárosová Uhrová
Anna Mészárosová Uhrová
ABAnezka Belohlavkova
Anezka Belohlavkova
BHBarbora Hermanovska
Barbora Hermanovska
PKPavel Krsek
Pavel Krsek

26 October 2024 in Epilepsia
Verified
Journal Article
Open access
MSMaurits W. C. B. Sanders
Maurits W. C. B. Sanders
BKBobby P.C. Koeleman
Bobby P.C. Koeleman
EBEva H. Brilstra
Eva H. Brilstra
FJFloor E. Jansen
Floor E. Jansen
SBSara Baldassari
Sara Baldassari
KBKees P. J. Braun
Kees P. J. Braun
We studied the distribution of germline and somatic variants in epilepsy surgery patients with (suspected) malformations of cortical development (MCD) who underwent surgery between 2015 and 2020 at University Medical Center Utrecht (the Netherlands) and pooled our data with four previously published cohort studies. Tissue analysis yielded a pathogenic variant in 203 of 663 (31%) combined cases. In 126 of 379 (33%) focal cortical dysplasia (FCD) type II cases and 23 of 37 (62%) hemimegalencephaly cases, a pathogenic variant was identified, mostly involving the mTOR signaling pathway. Pathogenic variants in 10 focal epilepsy genes were found in 48 of 178 (27%) FCDI/mild MCD/mMCD with oligodendroglial hyperplasia and epilepsy cases; 36 of these (75%) were SLC35A2 variants. Six of 69 (9%) patients without a histopathological lesion had a pathogenic variant in SLC35A2 (n = 5) or DEPDC5 (n = 1). A germline variant in blood DNA was confirmed in all cases with a pathogenic variant in tissue, with a variant allele frequency (VAF) of ~50%. In seven of 114 patients (6%) with a somatic variant in tissue, mosaicism in blood was detected. More than half of pathogenic somatic variants had a VAF < 5%. Further analysis of the correlation between genetic variants and surgical outcomes will improve patient counseling and may guide postoperative treatment decisions.

6 August 2025 in Epilepsia Open
Verified
Journal Article
Open access
MSMaurits W. C. B. Sanders
Maurits W. C. B. Sanders
MEMatyas Ebel
Matyas Ebel
ACAswin Chari
Aswin Chari
MFMerel Fleumer
Merel Fleumer
AVAnca M. Vasilica
Anca M. Vasilica
PKPavel Krsek
Pavel Krsek
Objectives: Timely referral and efficient presurgical evaluation are important to optimize postoperative seizure and developmental outcomes in epilepsy surgery patients. We aimed to identify determinants of time intervals from epilepsy diagnosis to referral to specialized centers and epilepsy surgery in children with malformations of cortical development (MCDs) and low‐grade epilepsy‐associated tumors (LEATs). Methods: We performed a retrospective cohort study in 3 European centers, including children with MCD or LEAT who underwent epilepsy surgery between 2010 and 2020. Primary endpoints were (1) time interval between epilepsy diagnosis and referral for presurgical evaluation, (2) duration of presurgical evaluation trajectory, and (3) time from diagnosis to surgery. The secondary endpoint was postoperative seizure outcome. In our primary analysis, we performed a multivariable Cox proportional hazards analysis and used histopathological diagnosis, age at first seizure, presence of developmental delay, 1st seizure classification, initial EEG and MRI findings, duration until drug resistance, and family history as covariates. Results: Of the 507 children included, 259 (51%) had an MCD and 248 (49%) had a LEAT. Earlier drug resistance and the presence of an MR‐visible epileptogenic lesion were associated with shorter times from diagnosis to referral and surgery, and later onset of seizures was associated with a shorter time to surgery. LEAT was associated with a shorter presurgical evaluation and shorter time to surgery. An older age at surgery, shorter time from diagnosis to surgery, and a histopathological diagnosis of FCDII and LEAT were all independently associated with better postoperative seizure outcome. Significance: Epilepsy surgery was performed earlier in children with MR‐visible lesions and early drug resistance, particularly those with LEAT, and a shorter duration to epilepsy surgery was associated with better seizure outcomes. Many patients were initially considered MRI‐negative in the referring center, highlighting the importance of early referral, epilepsy‐dedicated MRI protocols, and experienced neuroradiologists. Increasing awareness of timely referral and surgery benefits is crucial for improving outcomes. Plain Language Summary: Children with severe focal structural epilepsy who have not responded to medication often benefit from surgery, especially when they are referred early. This study of 507 children found that certain factors—such as visible brain abnormalities on the first MRI, especially a specific type of brain tumor (LEAT), early signs of drug resistance, and seizures starting later in childhood—were linked to shorter times from diagnosis to surgery and that shorter time to surgery was linked to better seizure outcomes. Many children whose initial MRIs appeared to be normal were later found to have an epileptogenic brain lesion when examined at specialized centers. Early referral, advanced imaging, and expert evaluation are key to improving postsurgical outcomes.